Mirum Pharmaceuticals (MIRM) Common Equity (2018 - 2026)

Mirum Pharmaceuticals' Common Equity history runs 9 years deep, the most recent figure standing at $242.5 million for Q1 2026.

• In Q1 2026, Common Equity rose 3.96% year-over-year to $242.5 million; the TTM figure through Mar 2026 stood at $242.5 million (up 3.96% YoY), while the FY2025 annual figure was $314.7 million, up 39.47% from the prior year.
• Common Equity for Q1 2026 stood at $242.5 million, down from $314.7 million in the prior quarter.
• The five-year high for Common Equity was $314.7 million in Q4 2025, with the low at $78.6 million in Q2 2023.
• The 5-year median for Common Equity is $232.0 million (2024), against an average of $207.5 million.
• The sharpest annual moves came in 2022 and 2023: Common Equity jumped 200.19% in 2022, then decreased 28.98% in 2023.
• Mirum Pharmaceuticals' Common Equity stood at $142.0 million in 2022, then soared by 75.07% to $248.7 million in 2023, then declined by 9.26% to $225.6 million in 2024, then soared by 39.47% to $314.7 million in 2025, then fell by 22.94% to $242.5 million in 2026.
• Business Quant data shows MIRM's Common Equity at $242.5 million in Q1 2026, $314.7 million in Q4 2025, and $292.0 million in Q3 2025.